|Age:||18 years or older|
|Keywords:||NSCLC, non-small cell lung cancer, EGFR-mutant non-small cell lung cancer, EGFR-mutant NSCLC|
|Type:||Other study, Phase 1|
All participants in this study (group 1 and 2) will receive AZD9291 and navitoclax (the study drugs) once a day by mouth on a 28 day cycle. Each day all participants will take AZD9291 and navitoclax at the same time with food.
The study doctor will tell you which group you can take part in.
Group 1: The first several study participants will receive the lowest dose of the study drugs. If the study drugs do not cause serious side effects, the drugs will be given to other participants at higher doses. The doses will continue to increase for each subgroup until side effects occur that require the dose to be lowered. Once a dose is identified that does not cause serious side effects, the next part of the study will begin.
Group 2: The dose of the study drugs you receive will depend on the best dose identified in the Group 1 part of this study.
Have any questions or want to learn more? Leave your contact details below and the research team will reach out to you.